Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial

Heart

Volumn 76, Issue 3, 1996, Pages 223-231

  Lubsen, J ^a  

^a SOCAR RESEARCH SA   (Switzerland)

Author keywords

Clinical trials; Exercise capacity; Heart failure; Pimobendan

Indexed keywords

PIMOBENDAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXERCISE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029742865     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.3.223     Document Type: Article

References (27)

1. Packer M. Treatment of chronic heart failure. Lancet 1992;340:92-5.
2. Kulka PJ, Tryba M. Inotropic support of the critically ill patient. A review of the agents. Drugs 1993;45:654-67.
3. Scholz H, Meyer W. Phosphodiesterase-inhibiting properties of newer inotropic agents. Circulation 1986;73: III-99-108.
4. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. N Engl J Med 1986;314:349-58.
5. The xamoterol in severe heart failure study group. Xamoterol in severe heart failure. Lancet 1990;336:1-6 [Erratum, Lancet 1990;336:698].
6. Uretsky BF, Jessup M, Konstam MA , Dec GW, Leier CV, Benotti J, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-80.
7. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
8. Hagemeijer F. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993;14:551-66.
9. Hasenfuss G, Holubarsch C, Heiss W, Just H. Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Am Heart J 1989;118:512-9.
10. Katz SD, Kubo SH, Jessup M, Brozena S, Troha JM, Wahl J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J 1992;123:95-103.
11. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, et al for the Pimobendan Multicenter Research Group. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. Circulation 1992;85:942-9.
12. Sasayama S, Asanoi H, Kihara Y, Yokawa S, Terada Y, Yoshida S, et al. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels 1994;9:113-20.
13. Remme WJ, Krayenbühl HP, Baumann G, Frick MH, Haehl M, Nehmiz G, et al for the Pimobendan-Enalapril Study Group. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. Eur Heart J 1994; 15:947-56.
14. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-8.
15. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown;1994:253-6.
16. Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure: Part 2. Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987;3: 198-209.
17. Morganroth J, Borland M, Chao G. Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 1987;59:97-9.
18. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart disease. A textbook of cardiovascular medicine. 4th ed. Philadelphia: WB Saunders, 1992:756-89.
19. Cleland JGF, Erhardt L, Hall AS, Winter C, Ball SG on behalf of the AIRE Study Investigators. Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. J Cardiovasc Pharmacol 1993;22 (suppl 9): S22-7.
20. Declaration of Helsinki. The World Medical Assembly, Inc. Ferney-Voltaire, France, September 1989.
21. Pearson ES, Hartley HO. Charts of the power function for analysis of variance tests derived from the non-Central F-distribution. Biometrika 1951;38:112-30.
22. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London: Blackwell, 1994:207-32.
23. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986:170-1.
24. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London: Blackwell, 1994:484-7.
25. Narang R, Swedberg K, Cleland JGF. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996;17:120-34.
26. Lubsen J. Exercise testing as outcome in congestive heart failure trials. Drugs 1994;7(suppl 4):25-30.
27. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993;22:1223-7.